Log in

Creo Medical Group Share Forecast, Price & News

GBX 172
-2.00 (-1.15 %)
(As of 09/18/2020 12:00 AM ET)
Today's Range
Now: GBX 172
50-Day Range
MA: GBX 182.80
52-Week Range
Now: GBX 172
Volume18,745 shs
Average Volume84,937 shs
Market Capitalization£271.06 million
P/E RatioN/A
Dividend YieldN/A
Creo Medical Limited develops and sells instruments for surgical endoscopy in the United Kingdom. The company is developing instruments for endoscopy through a combination of bipolar radiofrequency and microwave energy in a single platform for tissue dissection, resection, ablation, and coagulation. It offers Speedboat RS2 instrument for endoscopic submucosal dissection. Creo Medical Limited was formerly known as MicroOncology Ltd. The company was founded in 2003 and is based in Chepstow, the United Kingdom. Creo Medical Limited is a subsidiary of Creo Medical Group plc.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.10 out of 5 stars

Industry, Sector and Symbol

Industry Medical Devices



Sales & Book Value

Annual Sales£13,473.00
Price / Sales20,118.63
Cash FlowGBX 53.90 per share
Book ValueGBX 55 per share



Market Cap£271.06 million
Next Earnings DateN/A
OptionableNot Optionable
GBX 172
-2.00 (-1.15 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CREO News and Ratings via Email

Sign-up to receive the latest news and ratings for CREO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Creo Medical Group (LON:CREO) Frequently Asked Questions

How has Creo Medical Group's stock price been impacted by Coronavirus?

Creo Medical Group's stock was trading at GBX 143.50 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CREO stock has increased by 19.9% and is now trading at GBX 172.
View which stocks have been most impacted by COVID-19

How were Creo Medical Group's earnings last quarter?

Creo Medical Group PLC (LON:CREO) announced its quarterly earnings data on Tuesday, March, 20th. The company reported ($5.00) earnings per share (EPS) for the quarter.
View Creo Medical Group's earnings history

Who are some of Creo Medical Group's key competitors?

What other stocks do shareholders of Creo Medical Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Creo Medical Group investors own include Mysquare (MYSQ) and IQE (IQE).

Who are Creo Medical Group's key executives?

Creo Medical Group's management team includes the following people:
  • Mr. Craig Jonathan Gulliford, CEO & Director (Age 48)
  • Prof. Christopher Paul Hancock, Founder, CTO & Director (Age 51)
  • Mr. Richard John Rees ACA, CFO, Company Sec. & Director (Age 42)
  • Mr. Phil Hales, Sales & Marketing Director

What is Creo Medical Group's stock symbol?

Creo Medical Group trades on the London Stock Exchange (LON) under the ticker symbol "CREO."

How do I buy shares of Creo Medical Group?

Shares of CREO and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Creo Medical Group's stock price today?

One share of CREO stock can currently be purchased for approximately GBX 172.

How big of a company is Creo Medical Group?

Creo Medical Group has a market capitalization of £271.06 million and generates £13,473.00 in revenue each year. Creo Medical Group employs 50 workers across the globe.

What is Creo Medical Group's official website?

The official website for Creo Medical Group is creomedical.com.

How can I contact Creo Medical Group?

The company can be reached via phone at +44-1291-606005.

This page was last updated on 9/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.